SCHEMBL13628012

SCHEMBL13628012

Cc1cc(Cl)cc2c1N(Cc1csc(-c3ccc(Cl)cc3)n1)C(=O)/C2=N\O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.42
GFER P55789 1/20 0.41
KLKB1 P03952 1/20 0.40
KLK1 P06870 1/20 0.40
MAPT P10636 5/20 0.39
TP53 P04637 4/20 0.39
SCN9A Q15858 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAOB P27338 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
RHOC P08134 1/20 0.37
RHOA P61586 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627995 0.93 LMNA (0.42) LMNASMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL13627969 0.84 PTGDR2 (0.51) LMNASMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL13910738 0.83 SMN1; SMN2 (0.45) LMNASMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL13627963 0.80 LMNA (0.45) LMNASMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL13627979 0.79 PTGDR2 (0.46) LMNASMN1; SMN2KDM4ENPC1ALDH1A1
SCHEMBL13628003 0.76 MEN1 (0.46) LMNASMN1; SMN2ALDH1A1MAPTTP53
SCHEMBL13628013 0.75 CHRM5 (0.49) PTGDR2
SCHEMBL13627996 0.73 CHRM5 (0.50) SMN1; SMN2KDM4EMAPTTP53
SCHEMBL13628000 0.72 TP53 (0.42) ALDH1A1PTGDR2MAPTTP53
SCHEMBL13628001 0.71 CHRM5 (0.40) SMN1; SMN2KDM4EALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 LMNA 2123/4885SMN1; SMN2 3544/4885KDM4E 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.